Viking Therapeutics Shares Surge 50% On Positive Obesity Drug Data
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Viking Therapeutics' stock soared following the release of updated data from its obesity drug trial, indicating that trial participants mostly maintained their weight loss after switching from a weekly injection to a daily pill. In contrast, shares of competitors Eli Lilly rose while Novo Nordisk experienced a decline.
The positive results from Viking's study have positioned the company favorably in the competitive obesity treatment market, attracting significant investor interest and leading to a notable increase in its stock price.
Viking TherapeuticsEli LillyNovo Nordisk
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“<figure><div><img”
biopharma dive — Viking shares surge on updated obesity drug data
SupportCorroborates it
“Viking Therapeutics Skyrockets On Obesity Drug Data. Lilly Rises, But Novo Falls.”
Yahoo Finance — Viking Therapeutics Skyrockets On Obesity Drug Data. Lilly Rises, But Novo Falls.